PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33411033-0 2021 Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy. Platinum 46-54 ATPase copper transporting beta Homo sapiens 23-28 32570116-4 2020 Recent studies suggest that the copper efflux transporters ATP7A and ATP7B play an important role in platinum resistance. Platinum 101-109 ATPase copper transporting beta Homo sapiens 69-74 32570116-8 2020 Based on the results of in vitro assays, disease-relevant animal models, and clinical studies to date, it may be concluded that APT7A and ATP7B deserve further development as predictive markers of platinum resistance in ovarian cancer. Platinum 197-205 ATPase copper transporting beta Homo sapiens 138-143 32006874-6 2020 METHODS: We studied the expression of copper transporters CTR1, ATP7A and ATP7B which are presumably involved in the uptake, cellular transport and efflux of platinum compounds by immunofluorescence microscopy and flow-cytometry. Platinum 158-166 ATPase copper transporting beta Homo sapiens 74-79 29970670-0 2018 ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients. Platinum 64-72 ATPase copper transporting beta Homo sapiens 0-5 31790150-0 2019 Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity. Platinum 116-124 ATPase copper transporting beta Homo sapiens 17-22 31790150-3 2019 The resistance to platinum has been linked to the activity of divalent transporter ATP7B, which pumps platinum from the cytoplasm into lysosomes, decreasing its concentration in the cytoplasm. Platinum 18-26 ATPase copper transporting beta Homo sapiens 83-88 31790150-3 2019 The resistance to platinum has been linked to the activity of divalent transporter ATP7B, which pumps platinum from the cytoplasm into lysosomes, decreasing its concentration in the cytoplasm. Platinum 102-110 ATPase copper transporting beta Homo sapiens 83-88 30310510-0 2018 Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients. Platinum 80-88 ATPase copper transporting beta Homo sapiens 54-59 30310510-3 2018 Recent studies suggest that ATP7B, a copper efflux transporter, may be involved in platinum resistance. Platinum 83-91 ATPase copper transporting beta Homo sapiens 28-33 30310510-5 2018 Moreover, the effects of single nucleotide polymorphisms (SNPs) in ATP7B gene on the response to platinum-based chemotherapy are scarcely understood. Platinum 97-105 ATPase copper transporting beta Homo sapiens 67-72 30310510-14 2018 Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients. Platinum 73-81 ATPase copper transporting beta Homo sapiens 39-44 30310510-14 2018 Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients. Platinum 73-81 ATPase copper transporting beta Homo sapiens 108-113 30310510-14 2018 Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients. Platinum 201-209 ATPase copper transporting beta Homo sapiens 39-44 30310510-14 2018 Conclusion: Our findings indicate that ATP7B rs9526814 may contribute to platinum resistance by influencing ATP7B gene expression and can be used as a potential biomarker to predict the sensitivity of platinum-based chemotherapy in NSCLC patients. Platinum 201-209 ATPase copper transporting beta Homo sapiens 108-113 29394468-0 2018 Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy. Platinum 65-73 ATPase copper transporting beta Homo sapiens 37-42 29394468-3 2018 Recent studies suggest that copper efflux transporters, which are encoded by ATP7A and ATP7B, play an important role in platinum drug resistance. Platinum 120-128 ATPase copper transporting beta Homo sapiens 87-92 29970670-3 2018 The two P-type ATPases ATP7A and ATP7B have been identified to play an essential role in the transport of platinum. Platinum 106-114 ATPase copper transporting beta Homo sapiens 33-38 29970670-5 2018 In this study, we aimed to investigate the association of ATP7A and ATP7B genetic polymorphisms with clinical outcome and toxicity of platinum-based chemotherapy in NSCLC patients. Platinum 134-142 ATPase copper transporting beta Homo sapiens 68-73 29970670-13 2018 Conclusion: The genotypes of ATP7B gene may be novel and significant biomarkers for predicting the gastrointestinal toxicity of platinum-based chemotherapy in NSCLC patients. Platinum 128-136 ATPase copper transporting beta Homo sapiens 29-34 24023303-0 2013 Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer. Platinum 46-54 ATPase copper transporting beta Homo sapiens 11-16 24852429-0 2014 The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Platinum 60-68 ATPase copper transporting beta Homo sapiens 4-9 24852429-1 2014 This study aims to investigate the influence of ATP7B genetic polymorphism to platinum-based chemotherapy in Chinese Han lung cancer patients. Platinum 78-86 ATPase copper transporting beta Homo sapiens 48-53 24852429-4 2014 Four tag SNPs of ATP7B (rs1061472, rs9535826, rs7999812, and rs9535828) were selected to evaluate their impacts to platinum-based chemotherapy in these patients. Platinum 115-123 ATPase copper transporting beta Homo sapiens 17-22 24852429-5 2014 ATP7B rs9535828 and rs9535826 were found to be associated with platinum resistance in Chinese Han lung cancer patients. Platinum 63-71 ATPase copper transporting beta Homo sapiens 0-5 24852429-6 2014 Patients with A allele in ATP7B rs9535828 presented an increased susceptibility to platinum drugs (OR 1.96, 95 % CI 1.17-3.30, p < 0.01). Platinum 83-91 ATPase copper transporting beta Homo sapiens 26-31 24852429-7 2014 Patients with G allele in ATP7B rs9535826 had the highest susceptibility to platinum drugs (OR 2.05, 95 % CI 1.19-3.52, p < 0.01). Platinum 76-84 ATPase copper transporting beta Homo sapiens 26-31 24852429-8 2014 Our findings suggest that ATP7B genetic polymorphisms could affect the therapeutic efficacy of platinum-based chemotherapy, and ATP7B gene might be considered as predictive markers for the efficacy evaluation of platinum-based chemotherapy in Chinese Han lung cancer patients. Platinum 95-103 ATPase copper transporting beta Homo sapiens 26-31 24852429-8 2014 Our findings suggest that ATP7B genetic polymorphisms could affect the therapeutic efficacy of platinum-based chemotherapy, and ATP7B gene might be considered as predictive markers for the efficacy evaluation of platinum-based chemotherapy in Chinese Han lung cancer patients. Platinum 212-220 ATPase copper transporting beta Homo sapiens 128-133 28737129-0 2017 Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer. Platinum 70-78 ATPase copper transporting beta Homo sapiens 60-65 27748801-7 2016 Among the genes involved in platinum or taxane resistance (MDR1, ABCG2, MRP2 or ATP7B), MDR1 was uniquely overexpressed in all the resistant cells. Platinum 28-36 ATPase copper transporting beta Homo sapiens 80-85 25242165-8 2014 Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper. Platinum 13-21 ATPase copper transporting beta Homo sapiens 86-91 24023303-6 2013 Results were correlated with response to platinum-based chemotherapy: 65% of patients exhibited LOH of the ATP7B locus on chromosome 13q14.3, with a tendency to have a better response to chemotherapy. Platinum 41-49 ATPase copper transporting beta Homo sapiens 107-112 22966294-1 2010 Copper-transporting P-type adenosine triphosphatase (ATP7B) is reportedly associated with platinum drug resistance in various solid tumors. Platinum 90-98 ATPase copper transporting beta Homo sapiens 53-58 21455266-5 2011 Active platinum efflux catalyzed by ATP7B is unlikely to significantly contribute to cisplatin resistance in vivo. Platinum 7-15 ATPase copper transporting beta Homo sapiens 36-41 23751120-7 2013 Transfer of platinum along the copper-transport pathways in the cell may serve as a mechanism of drug delivery to its target in the cell nucleus, and explain tumour-cell resistance to cisplatin associated with the overexpression of copper transporters ATP7B and ATP7A. Platinum 12-20 ATPase copper transporting beta Homo sapiens 252-257 19296535-1 2009 Recently, the copper efflux transporters ATP7B and ATP7A have been implicated in the transport of and resistance to platinum drugs in breast and ovarian cancers. Platinum 116-124 ATPase copper transporting beta Homo sapiens 41-46 19509135-2 2009 Several other Cu transporters, including the influx transporter CTR1 and the two efflux transporters ATP7A and ATP7B, also regulate sensitivity to the platinum-containing drugs. Platinum 151-159 ATPase copper transporting beta Homo sapiens 111-116 19470734-2 2009 Here, we examined the biological mechanisms and therapeutic potential of targeting a critical platinum resistance gene, ATP7B, using both in vitro and in vivo models. Platinum 94-102 ATPase copper transporting beta Homo sapiens 120-125 20045993-1 2009 ATP7A and ATP7B are involved in cellular resistance to platinum compounds such as cisplatin. Platinum 55-63 ATPase copper transporting beta Homo sapiens 10-15 15213293-8 2004 These results demonstrate that both ATP7A and ATP7B modulate the pharmacodynamics of all three clinically used platinum drugs. Platinum 111-119 ATPase copper transporting beta Homo sapiens 46-51 18636185-1 2008 Copper-transporting P-type adenosine triphosphatase (ATP7B) is reportedly associated with platinum drug resistance in various solid carcinomas. Platinum 90-98 ATPase copper transporting beta Homo sapiens 53-58 18636185-2 2008 However, the impact of ATP7B on platinum drug resistance in non-small cell lung cancer (NSCLC) remains unknown. Platinum 32-40 ATPase copper transporting beta Homo sapiens 23-28 15240550-5 2004 There was greater sequestration of Pt into intracellular vesicles in the 2008/ECFP-ATP7B cells than in the 2008/ECFP cells. Platinum 35-37 ATPase copper transporting beta Homo sapiens 83-88 34347217-1 2022 BACKGROUND: Platinum agents are taken up into cells by copper transporter (CTR) 1 (gene code: SLC31A1) and are excreted from cells by copper-transporting P-type adenosine triphosphatase (ATP7B) and multidrug resistance-associated protein (MRP) 2 (gene code: ABCC2). Platinum 12-20 ATPase copper transporting beta Homo sapiens 187-192 35053335-0 2022 TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells. Platinum 43-51 ATPase copper transporting beta Homo sapiens 15-20 35053335-3 2022 In addition to liver, high ATP7B expression has been reported in tumors with elevated resistance to platinum (Pt)-based chemotherapy. Platinum 100-108 ATPase copper transporting beta Homo sapiens 27-32 35053335-5 2022 Although the mechanisms underlying Pt-tolerance are still ambiguous, accumulating evidence suggests that lysosomal sequestration of Pt drugs by ion transporters (including ATP7B) might significantly contribute to drug resistance development. Platinum 132-134 ATPase copper transporting beta Homo sapiens 172-177 35053335-8 2022 Using resistant ovarian cancer IGROV-CP20 cells, we found that TFEB directly binds to the predicted coordinated lysosomal expression and regulation (CLEAR) sites in the proximal promoter and first intron region of ATP7B upon Pt exposure. Platinum 225-227 ATPase copper transporting beta Homo sapiens 214-219